For example, the SOUND trial investigated the feasibility of omitting SLNB in postmenopausal hormone receptor positive, HER2-negative breast cancer patients eligible for breast-conserving surgery with a negative preoperative axillary ultrasound and found no adverse effect on 5-year distant disease-free survival [24,25]. Here, ERBB2 is linked to breast carcinoma.